Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, West Yorkshire BD7 1DP, UK.
Curr Top Med Chem. 2009;9(16):1494-524. doi: 10.2174/156802609789909812.
CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and potential in the design of new anticancer therapeutics. The natural products and their analogues exert their effects through a sequence selective alkylation of duplex DNA in the minor groove at the N3 of adenine. An understanding of their structure and its effect on biological activity has been derived through chemical synthesis and has also generated new potential lead compounds. These studies form the first section of the review. The desire to progress these compounds to clinic has also led to studies of bioconjugation and prodrug formation and this is discussed in the second section of the review. The combination of synthesis with key biological experiments is a powerful tool to define the requirements for the development of natural products as potential therapeutic agents. The studies described herein form an excellent paradigm for the study and development of other natural products.
CC-1065、duocarmycins 和 yatakemycin 是一组超强抗肿瘤抗生素的成员,由于它们的作用模式和在设计新型抗癌治疗药物方面的潜力,这些抗生素一直是广泛研究的对象。天然产物及其类似物通过在腺嘌呤的 N3 处小沟中的双链 DNA 上进行序列选择性烷基化来发挥作用。通过化学合成对其结构及其对生物活性的影响的理解已经衍生出来,并产生了新的潜在先导化合物。这些研究构成了综述的第一部分。将这些化合物推进临床应用的愿望也导致了生物缀合和前药形成的研究,这在综述的第二部分进行了讨论。将合成与关键生物学实验相结合是定义将天然产物开发为潜在治疗剂的要求的有力工具。本文所述的研究为其他天然产物的研究和开发提供了一个极好的范例。